Maynard Um
-
-
-
-
-
-
-
Gilead Sciences issues $3 billion in senior notes across four tranches
-
-
-
-
-
-
-
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD), flags Yeztugo risks
-
-
-
-
-
-
-
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on Likely Positive Call
-
-
-
-
-
-
-
Galapagos enters partnership with Gilead for autoimmune drug development
-
-
-
-
-
-
-
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - FT
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Gilead Sciences (GILD) Following ACLX Acquisition Announcement
-
-
-
-
-
-
-
Gilead Sciences (GILD) PT Raised to $175 at UBS
-
396,938 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

